Composite carbon dot carrier and VEGF (vascular endothelial growth factor) siRNA (small interfering Ribonucleic Acid)-carrying carbon dot complex
By preparing the FA-PEI-Gd-CDs vector and VEGF siRNA, the problem of early diagnosis and treatment of liver cancer is solved, the combination of dual-modal imaging and gene therapy is achieved, the shortcomings of the existing technology are overcome, and the diagnosis and treatment of liver cancer is improved. efficiency.
Patent Information
- Application Number
- CN202411214576.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-01
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-01
AI Technical Summary
The prior art has many shortcomings in the treatment and monitoring of liver cancer, including low sensitivity to early diagnosis of liver cancer, large side effects of traditional treatment methods, difficulty in achieving early lesions detection and effective treatment, and existing Gd-CDs are emitted in short-wavelength zones. It also has strong interference with the organism's autofluorescence, which limits its application.
By preparing a composite carbon dot carrier FA-PEI-Gd-CDs, it is prepared by solubilizing cysteine, neutral red and gadodiamine by solvothermal method, combined with PEI and folic acid molecules to form a bisect with long wavelength emission Modal imaging probes and binding to VEGF siRNA, the gene complex FA-PEI-Gd-CDs@VEGF siRNA was constructed to achieve the binding of bimodal imaging and gene therapy.
It realizes the efficient fluorescence-magnetic resonance imaging ability and cell transfection ability of dual-modal imaging, can penetrate living tissues, has excellent cell internalization ability and biosafety, effectively inhibits the growth of liver tumor cells, and improves liver cancer Diagnosis and treatment efficiency.
Smart Images

Figure CN119033971A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nanomaterials and biomedicine, and relates to a composite carbon dot with dual-modal imaging function and a gene-carrying complex constructed by using the composite carbon dot to carry VEGF siRNA, as well as applications in liver cancer treatment and imaging monitoring. Background Art
[0002] Liver cancer is one of the most common cancers with a very high mortality rate. Survey data show that in 2020, there were approximately 900,000 new cases of liver cancer worldwide, accounting for 4.69% of global cancer incidence, with an incidence rate of 9.5 / 100,000. By 2040, the number of new liver cancer cases and deaths worldwide may increase by 55% compared to now.
[0003] The liver itself lacks nerve wrapping, and even if there are symptoms in the early stages of liver cancer, they are relatively common symptoms such as abdominal distension, indigestion, and loss of appetite. Most liver cancer patients (about 70%) are already in the late stage when they are discovered and cannot undergo surgical resection. They can only be treated through other methods including liver transplantation, transcatheter arterial chemoembolization (TACE) or systemic chemotherapy. However, insufficient liver supply has limited the clinical application of liver transplantation, TACE cannot completely embolize tumor blood vessels, the postoperative hypoxic microenvironment leads to tumor progression, recurrence and even metastasis, and systemic chemotherapy has serious side effects and poor overall prognosis, all of which can lead to the failure of liver cancer treatment.
[0004] At the same time, current clinical monitoring of liver cancer mainly relies on traditional examination methods, which have low sensitivity to tiny lesions, making it difficult to detect early lesions, and cannot correctly evaluate tumor proliferation or inhibition to achieve "prescribing drugs according to cancer."
[0005] Therefore, exploring a tumor diagnosis and treatment technology that integrates liver cancer treatment and imaging monitoring can not only accurately diagnose the disease in real time and provide treatment, but also monitor the efficacy of the treatment process in real time and adjust the treatment plan in a timely manner, which can play an important role in improving the efficiency of liver cancer treatment and monitoring.
[0006] Vascular Endothelial Growth Factor (VEGF) is a highly specific vascular endothelial cell growth factor that promotes vascular permeability, extracellular matrix degeneration, endothelial cell proliferation and migration, and angiogenesis. Studies have found that VEGF-mRNA is overexpressed in liver cancer and is closely related to the proliferation, infiltration, and recurrence of liver cancer.
[0007] Gene therapy is a new type of treatment method. It transfers exogenous double-stranded small interfering RNA (siRNA) to the patient's special receptor cells to form an RNA-induced silencing complex, specifically silences the target gene mRNA, and inhibits tumor growth at the genetic level. It has the advantages of high specificity, few side effects, and heritability of the effect. Targeting VEGF, designing and synthesizing VEGF-siRNA and introducing it into liver cancer cells can inhibit the expression of VEGF-mRNA through siRNA, reduce the synthesis of VEGF, and block tumor angiogenesis, thereby improving the long-term efficacy of cancer and prolonging the survival of patients.
[0008] However, the medical application of siRNA is severely hampered by its inherent physicochemical properties, such as low charge density, high structural rigidity, and rapid enzymatic degradation.
[0009] Carbon dots (CDs) can effectively protect genes from degradation and achieve efficient gene silencing due to their easy surface functionalization, high biocompatibility and stability. Therefore, a CDs-based vector was developed to combine with VEGF siRNA to form a gene silencing complex for application in gene therapy of liver cancer.
[0010] On the other hand, CDs are not only excellent targeted fluorescent probes, but also gadolinium-doped carbon dots (Gd-CDs) synthesized after CDs are modified with paramagnetic metal ions such as gadolinium ions can be endowed with magnetic resonance imaging (MRI) capabilities, realizing fluorescence-magnetic resonance dual-modality imaging (Fluorescence Imaging-MRI, FLI-MRI). Dual-modality imaging probes can simultaneously provide high-resolution macroscopic anatomical information and highly sensitive microscopic optical signals, and have the advantages of integration and cross-validation, which can provide guarantees for the early diagnosis of liver cancer.
[0011] However, most of the current Gd-CDs emit in the short wavelength region. For example, the blue light Gd-CDs prepared by Du et al. (Du Jinglei, et al., Folic acid functionalized gadolinium-doped carbon dots as fluorescence / magnetic resonance imaging contrast agent for targeted imaging of liver cancer[J], Colloids and Surfaces B: Biointerfaces, 2023, 113721.) for targeted liver cancer FLI-MRI research not only have an optimal emission wavelength of 456nm, but also have weak fluorescence penetration ability into tissues. They are also interfered by the body's own fluorescence, which limits their application in tumor diagnosis and treatment.
[0012] Therefore, in order to overcome the defects and drawbacks of liver cancer monitoring and treatment at this stage and improve the application of nanomaterials in biomedicine, by constructing a reasonable long-wavelength emission Gd-CDs carrier system, establishing an efficient and safe siRNA delivery system and delivery method, and combining dual-modal imaging with gene therapy, it is of great significance to achieve integrated diagnosis and treatment of liver cancer. Summary of the invention
[0013] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a composite carbon dot carrier, which not only has a dual-modal imaging function but also has good gene-carrying ability.
[0014] Another purpose of the present invention is to use the composite carbon dot carrier to construct a carbon dot complex carrying VEGF siRNA.
[0015] The composite carbon dot carrier described in the present invention is based on Gd-CDs prepared by a one-step solvothermal method using cysteine, neutral red and gadolinium diamide, and polyethyleneimine (PEI) and folic acid (FA) molecules are coupled on its surface through activation with amide activators 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) to prepare a carrier FA-PEI-Gd-CDs.
[0016] Furthermore, the Gd-CDs are prepared by using cysteine, neutral red and gadolinium diamide as raw materials through a solvothermal reaction at 120-180° C. for 6-8 hours in an ethanol aqueous solution system.
[0017] Furthermore, the present invention specifically activates the Gd-CDs solution with EDC / NHS first, adds PEI to react, forms PEI-Gd-CDs by chemical bonds, and then adds FA, EDC and NHS to react in the dark, and prepares the composite carbon dot carrier FA-PEI-Gd-CDs by electrostatic bonding.
[0018] The composite carbon dot carrier FA-PEI-Gd-CDs prepared by the present invention has a positive charge, an emission wavelength of 604 nm, and has fluorescence-magnetic resonance dual-modal imaging capability, and can be used as a fluorescence-magnetic resonance dual-modal imaging probe.
[0019] The composite carbon dot carrier of the present invention has a long-wavelength emission fluorescence imaging effect and a high relaxation rate MRI imaging capability. It can not only penetrate living tissues for living fluorescence imaging and magnetic resonance imaging, but also enter cells for dual-modal imaging of cells. As a carrier, it also has excellent cell transfection ability and biosafety.
[0020] Furthermore, the VEGF siRNA-carrying carbon dot complex constructed by the present invention uses VEGF siRNA as the target gene and is carried on the composite carbon dot carrier FA-PEI-Gd-CDs by electrostatic adsorption to form a gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA.
[0021] Wherein, the target gene VEGF siRNA is a group of siRNAs having the following nucleotide sequences as shown in SEQ ID NO.5 and SEQ ID NO.6: Sense strand: 5′-GCAGAUCAUGCGGAUCAAA-3′; Antisense strand: 5′-UUUGAUCCGCAUGAUCUGC-3′.
[0022] In the VEGF siRNA-carrying carbon dot complex constructed by the present invention, the mass ratio of the composite carbon dot carrier FA-PEI-Gd-CDs to the target gene VEGF siRNA is preferably (4-10):1.
[0023] Furthermore, the optimal mass ratio of the composite carbon dot carrier FA-PEI-Gd-CDs to the target gene VEGF siRNA is 4:1, which can ensure that FA-PEI-Gd-CDs completely carry VEGF siRNA and avoid the occurrence of red blood cell adhesion.
[0024] The average particle size of the FA-PEI-Gd-CDs@VEGF siRNA constructed by the present invention is about 20 nm, and has good cell permeability.
[0025] The VEGF siRNA-carrying carbon dot complex of the present invention is prepared specifically according to the following method:
[0026] 1) Cysteine, neutral red and gadolinium diamide are added to a mixed solution of ethanol and water, and the mixture is subjected to a solvothermal reaction at 120-180°C for 6-8 hours. The reaction product is filtered, dialyzed and freeze-dried to obtain Gd-CDs powder;
[0027] 2) Gd-CDs were dissolved in PBS, amide activators EDC and NHS were added, and the mixture was allowed to stand at room temperature for 2-4 hours. After activation, PEI was added and stirred at 60-80°C for 4-8 hours. The reaction product was filtered, dialyzed, and freeze-dried to obtain PEI-Gd-CDs powder.
[0028] 3) Dissolve PEI-Gd-CDs, FA, EDC, and NHS in PBS, stir and react for 12 to 24 hours at room temperature in the dark, and filter, dialyze, and freeze-dry the reaction product to obtain FA-PEI-Gd-CDs solid powder;
[0029] 4) FA-PEI-Gd-CDs carrying positive charge and VEGF siRNA carrying negative charge were mixed and allowed to stand, and then combined by electrostatic interaction to form a gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA.
[0030] Specifically, in the above preparation method, the filtration is preferably performed using a disposable filter membrane with a pore size of 0.22 μm.
[0031] More specifically, in the above preparation method, it is preferred to use a dialysis bag with a molecular weight of 1000Da for dialysis.
[0032] The gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA constructed by the present invention can inhibit the expression of VEGF-mRNA and reduce the synthesis of VEGF through the siRNA it carries, and has an excellent gene silencing effect. Therefore, in addition to having good dual-modal imaging capabilities, the carbon dot complex carrying VEGF siRNA also has a specific inhibitory effect on liver tumor cells, and can be used to prepare drugs for inhibiting the growth of liver tumor cells, achieving a good therapeutic effect on liver cancer at the nanometer level.
[0033] Based on the good binding ability of FA-PEI-Gd-CDs and VEGF siRNA, the gene-carrying complex constructed by the present invention not only effectively avoids the effect of enzymatic degradation on VEGF siRNA in vivo, but also FA-PEI-Gd-CDs encapsulates VEGF siRNA and successfully enters cells and spreads in the cytoplasm, having excellent transfection ability and better inhibiting tumor growth and proliferation. At the same time, the FA-PEI-Gd-CDs@VEGF siRNA gene-carrying complex constructed by the present invention also has low toxicity and good biocompatibility.
[0034] Experiments have shown that the FA-PEI-Gd-CDs@VEGF siRNA gene-carrying complex constructed by the present invention exhibits excellent gene silencing effect and tumor inhibition ability on in vitro cells and in vivo tumor-bearing rabbit tumor models, and can well inhibit the activity of VEGF protein in tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 It is the XRD pattern of Gd-CDs powder.
[0036] Figure 2 These are the TEM and HRTEM images of the composite carbon dot carrier FA-PEI-Gd-CDs. The inset is the particle size statistics and the lattice image at a magnified multiple.
[0037] Figure 3 It is the FTIR spectra of Gd-CDs and FA-PEI-Gd-CDs.
[0038] Figure 4 It is the UV absorption spectra of Gd-CDs, FA-PEI-Gd-CDs and FA.
[0039] Figure 5 It is the fluorescence emission spectra of Gd-CDs, PEI-Gd-CDs and FA-PEI-Gd-CDs.
[0040] Figure 6 This is the full XPS spectrum of Gd-CDs.
[0041] Figure 7 This is the full XPS spectrum of FA-PEI-Gd-CDs.
[0042] Figure 8 is the Zeta potential of Gd-CDs, PEI, PEI-Gd-CDs, FA and FA-PEI-Gd-CDs.
[0043] Fig. 9 are T1-weighted images of Gd-CDs, FA-PEI-Gd-CDs, and gadodiamide.
[0044] Fig.10 It is the histogram of hemolysis rate of FA-PEI-Gd-CDs solution with different concentrations.
[0045] Fig.11 It is the histogram of cell survival rate of Gd-CDs and FA-PEI-Gd-CDs solutions with different concentrations.
[0046] Fig.12 These are the pathological sections of nude mouse organs after being treated with PBS and FA-PEI-Gd-CDs solutions for different time periods.
[0047] Fig.13 This is the body weight-time change curve of nude mice in different treatment groups.
[0048] Fig.14 The serum of nude mice was analyzed after being treated with PBS and FA-PEI-Gd-CDs solution for different time periods.
[0049] Fig.15 These are the laser confocal microscopy images and MRI images of FA-PEI-Gd-CDs in VX2 cells.
[0050] Fig.16 These are the time-dependent imaging images of nude mice in vivo after treatment with FA-PEI-Gd-CDs and the in vitro fluorescence images of organs at different times, as well as the in vivo MRI images of tumor-bearing mice after intravenous injection of FA-PEI-Gd-CDs.
[0051] Fig.17 This is a graph evaluating the anti-tumor proliferation ability of different VEGF siRNA sequences.
[0052] Fig.18 This is the TEM image of FA-PEI-Gd-CDs@VEGF siRNA, and the inset is the particle size statistics.
[0053] Fig.19 It is the agarose gel electrophoresis diagram of FA-PEI-Gd-CDs@VEGF siRNA with different mass ratios.
[0054] Fig. 20 These are the gel electrophoresis images of FA-PEI-Gd-CDs@VEGF siRNA and free siRNA with different mass ratios after being treated with FBS and RNase for different time periods.
[0055] Fig.21 These are the fluorescence imaging images of FA-PEI-Gd-CDs@VEGF siRNA in VX2 cells at different wavelengths and the intracellular fluorescence co-localization images.
[0056] Fig. 22This is a qualitative and quantitative analysis of VEGF protein expression after incubation with VX2 under different conditions.
[0057] Fig.23 is a histogram of cell survival rate after incubation with VX2 cells for 24 h under different conditions.
[0058] Fig.24 It is the CT image contrast and tumor inhibition rate before and after different treatment conditions.
[0059] Fig.25 This is a qualitative and quantitative analysis of VEGF protein expression in tumors after treatment under different conditions. Implementation
[0060] The specific implementation of the present invention is further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to more clearly illustrate the technical solution of the present invention so that those skilled in the art can well understand and utilize the present invention, rather than limiting the scope of protection of the present invention.
[0061] The production processes, experimental methods or detection methods involved in the embodiments of the present invention, unless otherwise specified, are all conventional methods in the prior art, and their names and / or abbreviations are all conventional names in the field, and are also very clear and unambiguous in the relevant application fields. Technical personnel in the field can understand the conventional process steps based on the names and apply the corresponding equipment, and implement them according to conventional conditions or the conditions recommended by the manufacturer.
[0062] The various instruments, equipment, raw materials or reagents used in the embodiments of the present invention are not particularly limited in terms of their sources, and are all conventional products that can be purchased through regular commercial channels, or can be prepared according to conventional methods well known to those skilled in the art. Example
[0063] Example 1
[0064] 1.2167g of cysteine, 58mg of neutral red, and 430mg of gadolinium diamide were weighed and added to a mixed solution consisting of 30mL of ethanol and 10mL of deionized water in sequence, and then transferred to a 100mL polytetrafluoroethylene-lined stainless steel reactor, and subjected to closed solvent thermal reaction at 140°C for 8h to obtain a light orange transparent solution. The reaction solution was filtered through a 0.22μm filter membrane, and then dialyzed for purification. Finally, the dialyzed product was freeze-dried to prepare Gd-CDs powder.
[0065] The crystallization properties of Gd-CDs were analyzed by X-ray diffractometer (XRD). Figure 1The XRD pattern of Gd-CDs showed a broad diffraction peak centered at 2θ=25.6°, which belongs to the (002) crystal plane of graphite, indicating that Gd-CDs have a partially disordered carbon structure, which is attributed to the presence of nitrogen-, sulfur-, and oxygen-containing functional groups. In addition, a small diffraction peak around 2θ=42.6° corresponds to the (100) crystal plane of graphite. The corresponding lattice distances of Gd-CDs on the (002) and (100) planes are approximately 0.37 and 0.21 nm, respectively.
[0066] Dissolve 20 mg of Gd-CDs in 20 mL of PBS to prepare a 1 mg / mL Gd-CDs solution, add 50 mg of EDC and 20 mg of NHS, and let stand at room temperature for 2 h after dissolution. After activation, add PEI to dissolve until the PEI concentration in the solution reaches 5 mg / mL, and stir in a 60°C water bath for 5 h to prepare a PEI-Gd-CDs solution. Filter through a 0.22 μm filter membrane, dialyze, and freeze-dry to prepare a PEI-Gd-CDs solid powder.
[0067] Weigh 24 mg FA, 12 mg PEI-Gd-CDs, 9 mg EDC and 9 mg NHS, dissolve in 30 mL PBS, react with stirring at room temperature in the dark for 24 h, filter through a 0.22 μm filter membrane, dialyze, and freeze-dry to prepare a composite carbon dot carrier FA-PEI-Gd-CDs solid powder.
[0068] Take 1 mg of FA-PEI-Gd-CDs powder, disperse it in anhydrous ethanol, take 10 µL and drop it onto a dedicated copper grid. After evaporation and drying, use a transmission electron microscope (TEM) to observe the morphology, size and microstructure of FA-PEI-Gd-CDs. The results are as follows: Figure 2 As shown in (a), FA-PEI-Gd-CDs is spherical in shape, well dispersed, and has no obvious aggregation. From the particle size statistics in the small window in the figure, it can be seen that the particle diameter is between 2.0 and 6.0 nm, and the average particle size is 3.71 ± 0.88 nm. Figure 2 High-resolution transmission electron microscopy (HRTEM) observation in (b) shows that the lattice fringe is 0.20 nm.
[0069] from Figure 3 The Fourier transform infrared (FTIR) spectrum of FA-PEI-Gd-CDs clearly shows that the FTIR spectrum of FA-PEI-Gd-CDs is different from that of Gd-CDs at 1072 cm -1 A strong absorption peak appeared at 1467-1647 cm, which was attributed to the CN stretching of amine groups (primary and secondary groups), indicating that PEI was grafted onto the surface of Gd-CDs. -1 Range and 2954cm -1The characteristic peak of FA appeared at 3375cm, corresponding to the aromatic ring stretching and CH of aminobenzoic acid and pyridine molecules; -1 The wide peak near 1647cm -1 The sharp peaks represent the NH and C=O stretching absorptions of amide, respectively, which means that FA is covalently linked through amide.
[0070] Gd-CDs, FA and FA-PEI-Gd-CDs powders were dispersed in PBS and their UV-Vis absorption spectra (UV-Vis) were tested. Figure 4 As shown, in addition to the absorption peak of Gd-CDs, FA-PEI-Gd-CDs also has a characteristic absorption peak of FA molecules at 364nm, and compared with Gd-CDs, its absorption peak is red-shifted, which may be due to the π-π electron transition of the C=C bond and the n-π electron transition of the C=O bond, thus once again proving that FA is bound to the surface of PEI-Gd-CDs through electrostatic interaction, verifying the successful loading of PEI and FA.
[0071] Gd-CDs, PEI-Gd-CDs and FA-PEI-Gd-CDs powders were dispersed in PBS, and their emission spectra were measured using a fluorescence spectrometer. Figure 5 (a), (b) and (c) respectively show the emission spectra of Gd-CDs, PEI-Gd-CDs and FA-PEI-Gd-CDs at different excitation wavelengths, proving that each solution has excitation-independent properties. The best emission wavelength of FA-PEI-Gd-CDs is 604nm, which is longer than the best emission wavelength of 456nm of the background technology.
[0072] Furthermore, the elemental compositions of Gd-CDs and FA-PEI-Gd-CDs were analyzed using X-ray photoelectron spectroscopy (XPS).
[0073] like Figure 6 As shown in (a), the binding energies of C1s, N1s, O1s, S2p and Gd4d exist in the full spectrum of Gd-CDs, indicating that it contains C, N, O, S and Gd elements. Figure 6 (b) is the high-resolution energy spectrum of C1s, where the peaks at 284.6, 287.1, and 288.0 eV correspond to CC / C=C, CO / CN, and C=O, respectively; Figure 6 (c) The high-resolution spectrum of N1s shows that there are two types of chemical states of N, located at 398.4 and 399.1 eV, corresponding to pyridinic N and pyrrolic N, respectively; from the high-resolution spectrum of O1s of Gd-CDs ( Figure 6(d) It can be seen that the peaks at 530.2 and 531.0 eV correspond to CO and C=O, respectively; Figure 6 (e) is the high-resolution spectrum of S2p, where the peaks at 162.9 and 163.8 eV confirm the existence of C=S and CS; the high-resolution spectrum of Gd4d ( Figure 6 (f) shows two peaks centered at 148.2 and 141.7 eV, which are consistent with the Gd(2p 5 / 2 ) and Gd(2p 3 / 2 ) have similar spectral patterns.
[0074] like Figure 7 As shown in (a), the binding energy of C1s, N1s, O1s, S2p and Gd4d also exists in the full spectrum of FA-PEI-Gd-CDs, among which the N1s content increases from 8.01% to 9.80%, which indirectly proves the loading of PEI. Figure 7 The high-resolution energy spectra of FA-PEI-Gd-CDs in (b~f) are compared with those of Gd-CDs. The increase in the CO / CN content in FA-PEI-Gd-CDs is due to the covalent bonding of Gd-CDs with FA to produce an amide bond, which further proves the loading of FA.
[0075] Gd-CDs, PEI, PEI-Gd-CDs, FA and FA-PEI-Gd-CDs were dispersed in aqueous solution, and the surface Zeta potential of different particles was measured by laser Doppler microelectrophoresis. Figure 8 As shown in the figure, both Gd-CDs and PEI carry positive charges, and the two are combined by chemical bonds to form PEI-Gd-CDs, and then combined with negatively charged FA through electrostatic interaction, finally preparing the positively charged composite carbon dot carrier FA-PEI-Gd-CDs, which lays the foundation for the subsequent combination with negatively charged cell membranes and siRNA.
[0076] Example 2
[0077] 1.2167g of cysteine, 86.6mg of neutral red, and 430mg of gadolinium diamide were weighed and added to a mixed solution consisting of 30mL of ethanol and 10mL of deionized water in sequence, and then transferred to a 100mL polytetrafluoroethylene-lined stainless steel reactor, and subjected to closed solvent thermal reaction at 140°C for 8h to obtain a light orange transparent solution. The reaction solution was filtered through a 0.22μm filter membrane, and then dialyzed for purification. Finally, the dialyzed product was freeze-dried to prepare Gd-CDs powder.
[0078] Dissolve 20 mg of Gd-CDs in 20 mL of PBS to prepare a 1 mg / mL Gd-CDs solution, add 50 mg of EDC and 20 mg of NHS, and let stand at room temperature for 4 hours after dissolution. After activation, add PEI to dissolve until the PEI concentration in the solution reaches 5 mg / mL, and stir in a 60°C water bath for 8 hours to prepare a PEI-Gd-CDs solution. Filter through a 0.22 μm filter membrane, dialyze, and freeze-dry to prepare a PEI-Gd-CDs solid powder.
[0079] Weigh 24 mg FA, 24 mg PEI-Gd-CDs, 9 mg EDC and 9 mg NHS, dissolve in 30 mL PBS, react with stirring at room temperature in the dark for 24 h, filter through a 0.22 μm filter membrane, dialyze, and freeze-dry to prepare a composite carbon dot carrier FA-PEI-Gd-CDs solid powder.
[0080] Example 3
[0081] 1.2167g of cysteine, 58mg of neutral red, and 480mg of gadolinium diamide were weighed and added to a mixed solution consisting of 30mL of ethanol and 10mL of deionized water in sequence, and then transferred to a 100mL polytetrafluoroethylene-lined stainless steel reactor, and the closed solvent was thermally reacted at 140°C for 6h to obtain a light orange transparent solution. The reaction solution was filtered through a 0.22μm filter membrane, and then dialyzed for purification. Finally, the dialyzed product was freeze-dried to prepare Gd-CDs powder.
[0082] 40 mg of Gd-CDs was dissolved in 20 mL of PBS to prepare a 2 mg / mL Gd-CDs solution, 50 mg of EDC and 20 mg of NHS were added, and the solution was allowed to stand at room temperature for 2 h after dissolution. After activation, PEI was added to dissolve the solution until the PEI concentration reached 5 mg / mL, and the solution was stirred in a 60°C water bath for 4 h to prepare a PEI-Gd-CDs solution. The solution was filtered through a 0.22 μm filter membrane, dialyzed, and freeze-dried to prepare a PEI-Gd-CDs solid powder.
[0083] 36 mg FA, 18 mg PEI-Gd-CDs, 9 mg EDC and 9 mg NHS were weighed and dissolved in 30 mL PBS. The mixture was stirred and reacted for 12 h at room temperature in the dark. The solid powder of composite carbon dot carrier FA-PEI-Gd-CDs was prepared by filtering through a 0.22 μm filter membrane, dialyzing and freeze-drying.
[0084] Example 4
[0085] In this example, the relaxivity of Gd-CDs and FA-PEI-Gd-CDs was first evaluated and compared with the relaxivity of the commercial product gadodiamide to verify the feasibility of Gd-CDs and FA-PEI-Gd-CDs as new MRI contrast agents.
[0086] like Fig. 9 As shown in (a), the MRI signal intensities of Gd-CDs, FA-PEI-Gd-CDs, and gadodiamide all increased with the increase of Gd 3+ The results show that the prepared Gd-CDs and FA-PEI-Gd-CDs can be used as new candidates for MRI. Fig. 9 As can be seen in (b), the image signals of Gd-CDs and FA-PEI-Gd-CDs are higher than that of Gd2O3.
[0087] From the linear relationship between the transverse relaxation rate (1 / T1) and the Gd concentration plotted in the figure, it can be calculated that the relaxation rate (slope) values of Gd-CDs, FA-PEI-Gd-CDs and gadodiamide are 7.97, 3.45 and 2.88 mM, respectively. -1 s -1 , indicating that Gd-CDs and FA-PEI-Gd-CDs have high relaxation rates and can be used in MRI, providing a basis for dual-modality imaging in vivo.
[0088] Secondly, this example uses UV-Vis detection to quantitatively analyze the hemolysis rate of FA-PEI-Gd-CDs solutions of different concentrations to examine their biocompatibility. The results are as follows: Fig.10 As shown in the figure, as the concentration of FA-PEI-Gd-CDs increased from 3.125 μg / mL to 200 μg / mL, the hemolysis rates were 1.2%, 1%, 0.6%, 2.4%, 2.9%, 2.9% and 3%, respectively. The measured values were all less than 5%, indicating that FA-PEI-Gd-CDs as a carrier has good blood compatibility.
[0089] This example also uses the standard CCK-8 method to evaluate the in vitro cytotoxicity of Gd-CDs and FA-PEI-Gd-CDs.
[0090] HepG2 (human liver cancer cells), VX2 (rabbit liver cancer cells) and HL-7702 (normal human liver cells) cells with good growth status were obtained, digested with trypsin, and diluted to 1×10 cells using complete culture medium. 5 / mL, 100µL per well was inoculated into a 96-well plate and cultured in a cell culture incubator until adhered. Gd-CDs and FA-PEI-Gd-CDs solutions of different concentrations (0, 25, 50, 100, 200µg / mL) were prepared in advance, and HepG2, VX2, and HL-7702 cells were incubated with them for 24h. After the culture, the cells were washed twice with PBS, and the CCK-8 solution prepared in advance was added to each well. After incubation for another 1h, the OD value of the solution was measured using a multifunctional microplate reader.
[0091] Fig.11 (a) and (b) show the survival rates of different cells after co-incubation with different concentrations of Gd-CDs and FA-PEI-Gd-CDs for 24 hours. Even when the concentration of Gd-CDs and FA-PEI-Gd-CDs was 200µg / mL, the survival rates of the three cells were still greater than 80%, indicating that Gd-CDs and FA-PEI-Gd-CDs have low cytotoxicity and good biocompatibility.
[0092] At the same time, the above experimental results also show that under some low-concentration conditions, the cell viability exceeded 100%, indicating that low-concentration Gd-CDs and FA-PEI-Gd-CDs have a certain effect in promoting cell proliferation.
[0093] Finally, BALB / c nude mice aged 6 to 8 weeks were selected as experimental animals to further verify the biosafety of FA-PEI-Gd-CDs as a carrier.
[0094] With normal saline as the control group and FA-PEI-Gd-CDs solution as the experimental group, the injection dose was 10 mg / Kg. The BALB / c nude mice were fed for 0, 1, 14, and 28 days, respectively, and then dissected. The brain, heart, liver, spleen, lung, kidney, and bladder were obtained to make tissue sections. The tissue sections were observed under a microscope to evaluate the pathological differences between the experimental and control groups. At the same time, the body weights of the two groups of BALB / c nude mice were monitored at different times (1, 3, 7, 14, 21, and 28 days) to indirectly verify the biosafety of FA-PEI-Gd-CDs.
[0095] Fig.12 (a) is the control group, and (b) is the experimental group. No obvious changes in cell status and inflammatory infiltration were found in both the control group and the experimental group, proving that FA-PEI-Gd-CDs has excellent biocompatibility.
[0096] In addition to tissue micromorphology, the weight growth curve is also an important indicator for testing biosafety in vivo, such as Fig.13 As shown, the weight gain trends of BALB / c nude mice in each group were similar within 28 days.
[0097] The biosafety of FA-PEI-Gd-CDs can be further elucidated by serum marker analysis. Blood was collected from the eyes of BALB / c nude mice injected with saline and FA-PEI-Gd-CDs solution for 1, 3, 14, and 28 days, respectively, after deep anesthesia. Blood routine and blood biochemistry analysis were performed to evaluate the content of white blood cells (WBC), hemoglobin concentration (HGB), and platelets (PLT); liver function and renal function parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (CREA), and urea nitrogen (UREA), were monitored.
[0098] Fig.14 In the study, there was no significant difference in WBC, PLT, and HGB between PBS and FA-PEI-Gd-CDs-treated BALB / c nude mice in the short-term and long-term after injection; AST, ALT, CREA, and UREA indexes increased slightly on the third day after injection of FA-PEI-Gd-CDs, but then decreased, which may be related to the body's clearance mechanism. No BALB / c nude mice died during the observation period, indicating that FA-PEI-Gd-CDs has a high in vivo biosafety, laying the foundation for its use as a carrier in in vivo research.
[0099] Example 5
[0100] In this example, VX2 cells were used for in vitro cell imaging studies, and confocal laser scanning microscope (CLSM) was used to observe the cell transfection effect of FA-PEI-Gd-CDs to evaluate the biological imaging and cell labeling capabilities of FA-PEI-Gd-CDs.
[0101] VX2 cells with good growth status were taken and dispersed into 1×10 4 2 mL of cell suspension of 100 μg / mL was transferred to a special culture dish with a pipette. After culturing in the incubator for 12 h, the culture medium was discarded, the cells were washed with PBS, and the cells were starved for 1 h in a culture medium containing 2% fetal bovine serum (FBS). The culture medium was discarded, the cells were washed with PBS, and complete culture medium containing FA-PEI-Gd-CDs (100 μg / mL) was added. The cells were cultured under the same conditions for 4 h, and paraformaldehyde was used to fix the cells for 15 min. CLSM was used for imaging. The results are shown in the figure. Fig.15 As shown in (a).
[0102] Among them, Bright is the cell distribution under bright field; FA-PEI-Gd-CDs is the cell distribution in the fluorescence field, and orange-red fluorescence can be clearly seen in the cells; Merge is the image after the bright field and the fluorescence field are superimposed, which proves that FA-PEI-Gd-CDs have entered the cells and are mainly distributed in the cytoplasm, indicating that FA-PEI-Gd-CDs has excellent cell transfection ability.
[0103] The MRI system was used to scan the cell fluid after VX2 cells were co-cultured with FA-PEI-Gd-CDs for 4 hours. VX2 cells with good growth status were cultured overnight on a 6-well plate, and different concentrations (0, 0.375, 0.75, 1.5, 3 mg / mL) of FA-PEI-Gd-CDs solution were added to each well and incubated for 4 hours. The cells were washed with PBS, digested with trypsin, centrifuged in EP tubes, and re-dispersed in 1% agarose solution for gelation before MRI was performed on a small animal magnetic resonance imaging instrument.
[0104] like Fig.15 As shown in (b), cells treated with FA-PEI-Gd-CDs exhibit bright images, and the brightness is positively correlated with the concentration of FA-PEI-Gd-CDs, indicating that FA-PEI-Gd-CDs has MRI capabilities, can be used as MRI contrast agents, and have a high relaxation rate.
[0105] Small animal in vivo imaging was used for observation to verify that the FA-PEI-Gd-CDs with long-wavelength emission of the present invention can penetrate living tissues for fluorescence imaging, and to observe their metabolic patterns after entering the body.
[0106] FA-PEI-Gd-CDs solution was injected into BALB / c nude mice at a dose of 10 mg / kg, and the in vivo fluorescence signals were recorded at 0, 0.5, 1, 2, 4, 8, 16, and 24 h using a small animal in vivo imaging device. Fig.16 As can be seen in (a), FA-PEI-Gd-CDs have reached all parts of the body with the blood 0.5 hours after injection, and the fluorescence intensity gradually increases with time, reaching the highest at 8 hours, and the fluorescence intensity in the kidney and bladder areas is the strongest. After 16 hours, the fluorescence intensity gradually weakened, and after 24 hours, the fluorescence basically disappeared, proving that FA-PEI-Gd-CDs are basically excreted from the body.
[0107] Furthermore, in vivo biodistribution is also a key factor in evaluating the in vivo biocompatibility of FA-PEI-Gd-CDs. BALB / c nude mice were killed at different times after injection of FA-PEI-Gd-CDs, and the main organs of brain, heart, liver, spleen, lung, kidney and bladder were collected at different time periods, and their biodistribution was studied by fluorescence imaging of isolated tissues.
[0108] like Fig.16 As shown in (b), the brain tissue began to fluoresce 0.5 hours after injection, the fluorescence intensity reached the highest at 2 hours, and the fluorescence gradually disappeared after 24 hours, indicating that FA-PEI-Gd-CDs can penetrate the blood-brain barrier of BALB / c nude mice and enter the brain tissue. At the same time, 2 hours after injection, a small part of FA-PEI-Gd-CDs can pass through different biological barriers and enter the liver and lungs, but the accumulation rate is relatively low. The kidneys and bladder began to fluoresce after 1 hour, and significantly decreased or even disappeared after 24 hours, indicating that FA-PEI-Gd-CDs can be cleared through rapid renal metabolism, further proving its good metabolism and strong biocompatibility.
[0109] Then, 10 mg / kg of FA-PEI-Gd-CDs solution was intravenously injected into BALB / c tumor-bearing mice, and then the tumor-bearing mice were scanned using a 3.0T magnetic resonance scanner. Fig.16 As can be seen in (c), after intravenous injection of FA-PEI-Gd-CDs, a short T1 high signal shadow was observed in the subcutaneous tumor area of the tumor-bearing mice, while a long T1 low signal shadow was observed in the subcutaneous tumor area of the tumor-bearing mice that were not injected with FA-PEI-Gd-CDs, indicating that the FA-PEI-Gd-CDs of the present invention can not only penetrate living tissues, but also have the characteristics of being able to target liver cancer tissues for MRI imaging.
[0110] Example 6
[0111] The sequence NM_001025366.3 encoding human VEGF cDNA (Homo sapiens vascular endothelialgrowth factor A) was searched in Gene Bank as the target gene. siRNA design software was used to design common targets for RNAi against different splicing variants of VEGF mRNA. Three sequences that were conducive to siRNA binding to form silencing complexes were selected: VEGF siRNA-599, VEGF siRNA-817, and VEGF siRNA-921. Three groups of siRNA fragments from different positions on the target gene mRNA were synthesized.
[0112] VEGF siRNA-599: Sense strand: 5′-CCUCCGAAACCAUGAACUU-3′; Antisense strand: 5′-AAGUUCAUGGUUUCGGAGG-3′.
[0113] VEGF siRNA-817: Sense strand: 5′-GAGUACAUAUUCAAGCCUU-3′; Antisense strand: 5′-AAGGCUUGAAUAUGUACUC-3′.
[0114] VEGF siRNA-921: Sense strand: 5′-GCAGAUCAUGCGGAUCAAA-3′; Antisense strand: 5′-UUUGAUCCGCAUGAUCUGC-3′.
[0115] Meanwhile, NC-VEGF siRNA was designed as a negative control, which has no obvious homology with human mRNA but has the same GC composition.
[0116] NC-VEGF siRNA: Sense strand: 5′-UUCUCCGAACGUGUCACGU-3′; Antisense strand: 5′-ACGUGACACGUUCGGAGAA-3′.
[0117] The above siRNAs were synthesized with the assistance of Shanghai Sangon Biotechnology Co., Ltd., and the base TT was added to the 3' end of each single strand.
[0118] Using NC-VEGF siRNA as a control, the anti-tumor proliferation ability of the different siRNAs designed above was evaluated at the in vitro cell level.
[0119] VX2 cells with good growth status were taken and 2×10 5 Cells were seeded per well in a 6-well plate and incubated overnight in an incubator. The medium was then changed to serum-free DMEM for 2 h before transfection.
[0120] The experiment was divided into 5 groups, group A was the normal cell group, group B was the NC-VEGF siRNA control group, group C was the VEGF siRNA-599 group, group D was the VEGF siRNA-817 group, and group E was the VEGF siRNA-921 group.
[0121] After grouping, transfection was performed on each group:
[0122] 10 μL of each group of siRNA and 5 μL of transfection reagent were diluted with 100 μL of serum-free DMEM medium, and after standing at room temperature for 5 minutes, the two solutions were mixed and stood for 20 minutes to obtain a mixed solution.
[0123] 200 μL of each mixed solution was added to the above 6-well plate, and the cells were cultured in the incubator for 6 hours, and then replaced with normal culture medium for further culture.
[0124] Total RNA was extracted from each group, reverse transcribed into cDNA, and real-time fluorescence quantitative PCR was used to detect mRNA in each group. -ΔΔCt The relative expression was calculated by Fig.17 The bar chart shown.
[0125] from Fig.17 The PCR results show that compared with the normal cell group and the NC-VEGF siRNA control group, VEGF siRNA-599 and VEGF siRNA-877 have no obvious silencing effect on the gene, but VEGF siRNA-921 has the strongest tumor inhibition effect, with a gene silencing effect of 62.4%, and a good gene silencing effect on liver cancer cells, which is statistically significant.
[0126] Therefore, the present invention screened out VEGF siRNA-921 from the three groups of gene sequences as the VEGF siRNA for constructing the final gene-carrying complex of the present invention.
[0127] Example 7
[0128] 160 μg of the FA-PEI-Gd-CDs composite carbon dot carrier solid powder prepared in Example 1 was weighed, dissolved in 1 mL of DEPC water, and filtered through a 0.22 μm filter membrane to obtain a FA-PEI-Gd-CDs solution.
[0129] 40 μg of the VEGF siRNA constructed in Example 6 was weighed into an EP tube, and the FA-PEI-Gd-CDs solution was added and mixed, and the mixture was allowed to stand on crushed ice for 1 h to allow the mixture to fully combine, thereby preparing a carbon dot complex FA-PEI-Gd-CDs@VEGF siRNA carrying the VEGF siRNA gene.
[0130] The prepared FA-PEI-Gd-CDs@VEGF siRNA was dropped onto a dedicated copper grid, and after evaporation and drying, the morphology and size were observed by TEM. Fig.18 The morphology of FA-PEI-Gd-CDs@VEGF siRNA is approximately ellipsoidal, and there is no aggregation phenomenon. The average particle size is about 19.52nm. Compared with FA-PEI-Gd-CDs, the particle size is significantly increased, which indirectly indicates that FA-PEI-Gd-CDs carries VEGF siRNA to form FA-PEI-Gd-CDs@VEGF siRNA.
[0131] Example 8
[0132] According to the method in Example 7, the FA-PEI-Gd-CDs solution was mixed with different masses of VEGF siRNA to prepare FA-PEI-Gd-CDs@VEGF siRNA with a mass ratio of 0.25:1, 0.5:1, 1:1, 2:1, 4:1, 8:1 and 10:1 of FA-PEI-Gd-CDs to VEGF siRNA, respectively.
[0133] After the FA-PEI-Gd-CDs@VEGF siRNA and DNA loading with different mass ratios were mixed, they were added to the sample wells for gel electrophoresis and imaged in a gel imager to confirm the binding ability between the composite carbon dot carrier and the gene in the FA-PEI-Gd-CDs@VEGFsiRNA with different mass ratios, proving that the gene can be completely loaded onto the carrier to construct a gene-loaded carbon dot complex.
[0134] Fig.19 In the figure, as the mass ratio gradually increases from 0.25:1 to 10:1, the bands in the sample wells gradually become brighter, while the brightness of the migration band gradually becomes darker. Starting from a mass ratio of 4:1, FA-PEI-Gd-CDs can completely retain VEGF siRNA in the sample wells, indicating that FA-PEI-Gd-CDs has good gene binding ability and also proves that the mass ratio of 4:1 is the critical composite ratio.
[0135] Example 9
[0136] FA-PEI-Gd-CDs@VEGF siRNA solutions with mass ratios of 4:1, 6:1, 8:1 and 10:1 were taken as experimental groups, free VEGF siRNA without FBS treatment was used as the control group, and free VEGF siRNA treated with FBS was used as the blank group to evaluate the protective effect of FA-PEI-Gd-CDs on VEGF siRNA in the presence of FBS.
[0137] Except for the control group, an equal volume of FBS (fetal bovine serum) was added to the solutions of the other groups, and the samples were cultured in the incubator for different time periods (0, 6, 12, 24, 48, and 72 hours), then taken out, and 1 mg / mL heparin sodium solution was added, and the samples were reacted in a metal bath at 37°C for 1 hour. The samples after the reaction were subjected to gel electrophoresis.
[0138] like Fig. 20As shown in (a), the free VEGF siRNA in the control group migrated at all time periods, while the migration brightness of the free VEGF siRNA in the blank group gradually decreased after 12 hours of treatment, and disappeared at 48 hours, indicating that VEGF siRNA without carrier protection is easily decomposed by nucleases in FBS. However, after 24 hours of treatment, the VEGF siRNA in the experimental group combined with FA-PEI-Gd-CDs of different mass ratios still showed obvious brightness in the sample wells, and the brightness in the sample wells completely disappeared after 72 hours, and the smaller the mass ratio, the earlier the brightness disappeared.
[0139] The above experimental phenomena indicate that FA-PEI-Gd-CDs@VEGF siRNA can effectively reduce the effects of enzymes in serum on VEGF siRNA.
[0140] Furthermore, FA-PEI-Gd-CDs@VEGF siRNA solutions with mass ratios of 4:1, 6:1, 8:1 and 10:1 were taken as experimental groups, free VEGF siRNA without RNase A treatment was used as the control group, and free VEGF siRNA treated with RNase A was used as the blank group to evaluate the protective effect of FA-PEI-Gd-CDs on VEGF siRNA in the presence of RNase A.
[0141] Except for the control group, 1U RNase A was added to the solutions of the other groups, and the mixture was shaken and mixed. After reacting in a 37℃ metal bath for 0, 0.5, 1, 2, and 3 hours, RNase inhibitor was added, and the reaction was continued in a 70℃ metal bath for 10 minutes. The samples after the reaction were subjected to gel electrophoresis experiments.
[0142] like Fig. 20 As shown in (b), the control group was completely free to form a bright migration band, but the blank group did not show any migration band at the beginning of the experiment, and no band brightness was seen in the sample wells, proving that the free VEGF siRNA had been degraded by RNase A. In each experimental group, the FA-PEI-Gd-CDs@VEGF siRNA with a mass ratio of 4:1 still had brightness in the sample wells after 0.5h of reaction, indicating that VEGF siRNA was not completely degraded; after 1h of reaction, the brightness in the sample wells with a mass ratio of 4:1 and 6:1 had disappeared, and after 2h, the brightness in the sample wells with a mass ratio of 8:1 also gradually disappeared, but after 3h of reaction, the sample wells with a mass ratio of 10:1 still had brightness, indicating that VEGF siRNA had not been completely degraded.
[0143] This proves that FA-PEI-Gd-CDs has a good binding effect with VEGF siRNA and can effectively avoid enzyme degradation in vivo.
[0144] Example 10
[0145] FAM-VEGF siRNA with 5' end fluorescently labeled was used with excitation wavelength of 492nm and emission wavelength of 518nm. It was combined with FA-PEI-Gd-CDs to construct fluorescently labeled FA-PEI-Gd-CDs@VEGF siRNA. The cell transfection ability of the gene-carrying carbon dot complex was investigated under laser confocal microscopy.
[0146] VX2 cells with good growth status were taken and dispersed into 1×10 4 2 mL of the cell suspension was transferred to a special culture dish with a pipette, placed in an incubator and cultured for 12 h, then the culture medium was discarded. After washing with PBS, the culture medium containing 2% fetal bovine serum (FBS) was added again and starved for 1 h, then the culture medium was discarded. After washing with PBS, complete culture medium containing FA-PEI-Gd-CDs@FAM-VEGF siRNA (100 µg / mL) was added and cultured under the same conditions for 4 h. The cells were fixed with paraformaldehyde for 15 min, and the cell transfection effect of FA-PEI-Gd-CDs@FAM-VEGF siRNA was observed under a laser confocal microscope.
[0147] Fig.21 In the figure, Bright is the cell distribution under bright field; the composite carbon dot carrier FA-PEI-Gd-CDs in FA-PEI-Gd-CDs@FAM-VEGF siRNA exhibits orange-red fluorescence (excitation wavelength 530nm, emission wavelength 604nm); FAM-VEGFsiRNA exhibits green fluorescence (excitation wavelength 492nm, emission wavelength 518nm); Merge1 is the image after superposition of fluorescence field; Merge2 is the image after superposition of bright field and fluorescence field.
[0148] It can be seen that FA-PEI-Gd-CDs@FAM-VEGF siRNA is dispersed in the cytoplasm, and further the co-localization analysis diagram in the lower right corner also shows that FA-PEI-Gd-CDs encapsulated VEGF siRNA successfully entered the cell and has good cellular internalization ability.
[0149] Embodiment 11
[0150] In this example, the in vitro anti-tumor effect of FA-PEI-Gd-CDs@VEGF siRNA was evaluated by detecting the changes in the expression of VEGF protein in cells using Western blotting (WB).
[0151] A total of 5 groups were set up in the experiment, among which A was the blank group; B was the FA-PEI-Gd-CDs group; C was the VEGF siRNA group; D was the FA-PEI-Gd-CDs@NC control group; and E was the FA-PEI-Gd-CDs@VEGF siRNA experimental group.
[0152] Take VX2 cells with good growth status and prepare a concentration of 1×10 5 / mL of cell suspension was inoculated into a 6-well plate, 2 mL per well. After overnight, the culture medium was discarded and replaced with low-concentration serum culture medium for starvation culture for 1 hour, and then washed 3 times with PBS.
[0153] Except for the blank group, the other groups were transfected with fresh culture medium of FA-PEI-Gd-CDs, VEGF siRNA, FA-PEI-Gd-CDs@NC, and FA-PEI-Gd-CDs@VEGF siRNA. After 4 h of transfection, culture medium containing a higher concentration of FBS was added and cultured for another 20 h. RIPA lysis buffer was added for 10 min to extract the protein and calculate its concentration.
[0154] After protein denaturation, electrophoresis, and transfer, the proteins were incubated with the primary antibody overnight at 4°C and with the secondary antibody for 1.5 h at room temperature. The protein level was detected by 3,3-diaminobenzidine (DAB) substrate colorimetric assay. The target band and internal reference A values were analyzed by ImageJ software, and the protein expression was expressed as the A ratio of the target protein to the β-actin internal reference to evaluate the VEGF expression level.
[0155] The silencing effect was compared using the stable β-actin protein expressed in the cells as the internal reference index. The qualitative analysis of the protein bands was as follows: Fig. 22 As shown in (a), the VEGF protein expression level of FA-PEI-Gd-CDs@VEGF siRNA is the lowest, proving that it can effectively inhibit the expression of VEGF protein.
[0156] The quantitative analysis results are as follows Fig. 22 As shown in (b), compared with the blank group of simple culture medium, the gene silencing effects of FA-PEI-Gd-CDs group, VEGF siRNA group and FA-PEI-Gd-CDs@NC group were not obvious and statistically insignificant. However, compared with the VEGF siRNA group and FA-PEI-Gd-CDs@NC group, the FA-PEI-Gd-CDs@VEGF siRNA group showed obvious gene silencing efficiency ( P <0.05).
[0157] This proves that the gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA of the present invention can inhibit the expression of VEGF-mRNA through its siRNA, reduce the synthesis of VEGF, and has an excellent gene silencing effect.
[0158] Furthermore, the CCK-8 method was used to investigate the inhibitory effect of FA-PEI-Gd-CDs@VEGF siRNA on the proliferation of HL-7702 cells and VX2 cells.
[0159] Take HL-7702 and VX2 cells with good growth status and prepare a concentration of 1×10 5 / mL cell suspension, 100 μL per well was inoculated into a 96-well plate, cultured overnight, washed twice with PBS, and 100 μL of each experimental group solution dissolved in complete culture medium was added to each well, and incubated for 24 hours. After the culture, PBS was washed twice, and the pre-prepared CCK-8 solution was added to each well and incubated for 1 hour, and the OD value of the solution was measured using a multifunctional microplate reader.
[0160] Fig.23 For normal HL-7702 cells, none of the groups caused cell death, and the cell survival rates of each group were similar, all greater than 80%; however, for tumor cells VX2, compared with the other groups that also did not cause cell death, the survival rate of VX2 cells in the FA-PEI-Gd-CDs@VEGF siRNA group was significantly reduced to only 42.3%.
[0161] This conclusion is consistent with the above-mentioned WB experimental results, confirming that the gene-carrying complex has a specific inhibitory effect on tumor cells.
[0162] Example 12
[0163] This example evaluates the in vivo anti-tumor effect of FA-PEI-Gd-CDs@VEGF siRNA.
[0164] The tumor-bearing rabbits with successful implantation and tumors with a maximum transverse diameter of 1 to 2 cm were randomly divided into two groups, A and B. Group A was the polyvinyl alcohol embolization microsphere group, and group B was the polyvinyl alcohol embolization microsphere + FA-PEI-Gd-CDs@VEGF siRNA group.
[0165] The tumor-bearing rabbits were anesthetized, the surgical area was prepared and disinfected, the right femoral artery was freed, and a 5F arterial sheath was inserted through the femoral artery by Seldinger puncture method, and a 4F catheter was inserted along the 5F catheter sheath. The celiac artery was angiography under the guidance of DSA. After the course of the hepatic artery was confirmed, the hepatic artery was superselected for angiography, and the frame rate was 6 / s. The blood supply of the tumor was confirmed by photography, and the microcatheter was superselected to the tumor supply artery, and the treatment was carried out according to the grouping method. CT scanning was used to monitor the tumor growth of the tumor-bearing rabbits 2 to 3 weeks after treatment in each group.
[0166] Fig.24 (a) shows the CT images of different treatment groups before and after treatment. It can be seen that compared with before treatment, the maximum transverse diameter of the tumor in both groups A and B has decreased to varying degrees. Further quantitative analysis of the inhibitory effect of different treatment groups on tumors showed that Fig.24 As shown in (b), the tumor inhibition rate of the polyvinyl alcohol embolization microspheres + FA-PEI-Gd-CDs@VEGF siRNA group was higher, indicating that FA-PEI-Gd-CDs@VEGF siRNA has a good gene silencing effect and can effectively inhibit tumor growth and proliferation.
[0167] The tumor-bearing rabbits in each group were killed by air embolism, and the tumor tissues were collected. The changes of VEGF expression in tumor tissues were detected by WB.
[0168] Qualitative analysis of protein bands Fig.25 As shown in (a), the silencing effect was compared using the β-actin protein that was stably expressed in the tissue as the internal reference index. The color of the VEGF protein band in group B was significantly lighter, proving that FA-PEI-Gd-CDs@VEGF siRNA could effectively inhibit the expression of VEGF protein. The quantitative analysis results are shown in Fig.25 As shown in (b), the expression rate of VEGF protein in group A was about 73.7%, and that in group B was about 24.1%, with significant difference between the two groups. P <0.1.
[0169] Through WB experiments, it was verified again that the polyvinyl alcohol embolization microspheres + FA-PEI-Gd-CDs@VEGF siRNA group can effectively inhibit the activity of VEGF protein in tumor cells.
[0170] The above embodiments of the present invention do not describe all the details in detail, nor limit the present invention to the above embodiments. Various changes, modifications, substitutions and variations made by ordinary technicians in this field without departing from the principles and purpose of the present invention should be included in the protection scope of the present invention.
Claims
1. A composite carbon dot carrier, which is based on Gd-CDs prepared by a one-step solvothermal method using cysteine, neutral red and gadolinium diamide, and polyethyleneimine and folic acid molecules are coupled on its surface through amide activators EDC and NHS activation to prepare the carrier FA-PEI-Gd-CDs.
2. The composite carbon dot carrier according to claim 1, wherein the Gd-CDs are prepared by using cysteine, neutral red and gadolinium diamide as raw materials through a solvothermal reaction at 120 to 180° C. for 6 to 8 hours in an ethanol aqueous solution system.
3. The composite carbon dot carrier according to claim 1 or 2, characterized in that First, the Gd-CDs solution is activated with EDC / NHS, and PEI is added for reaction to form PEI-Gd-CDs by chemical bonds. Then, FA, EDC and NHS are added simultaneously to react in the dark, and the composite carbon dot carrier FA-PEI-Gd-CDs is prepared by electrostatic bonding.
4. Use of the composite carbon dot carrier according to claim 1 as a fluorescence-magnetic resonance dual-modality imaging probe.
5. The VEGF siRNA-carrying carbon dot complex constructed by using the composite carbon dot carrier of claim 1 is a gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA formed by carrying VEGF siRNA as a target gene on the composite carbon dot carrier FA-PEI-Gd-CDs through electrostatic adsorption; The target gene VEGF siRNA is a group of siRNAs having the following nucleotide sequences as shown in SEQ ID NO.5 and SEQ ID NO.6: Sense strand: 5′-GCAGAUCAUGCGGAUCAAA-3′; Antisense strand: 5′-UUUGAUCCGCAUGAUCUGC-3′.
6. The VEGF siRNA-carrying carbon dot complex according to claim 5, characterized in that The mass ratio of the composite carbon dot carrier FA-PEI-Gd-CDs to the target gene VEGF siRNA is (4-10):
1.
7. The VEGF siRNA-carrying carbon dot complex according to claim 5 or 6, characterized in that The mass ratio of the composite carbon dot carrier FA-PEI-Gd-CDs to the target gene VEGF siRNA is 4:
1.
8. The method for preparing the VEGF siRNA-carrying carbon dot complex according to claim 5, comprising: 1) Cysteine, neutral red and gadolinium diamide are added to a mixed solution of ethanol and water, and the mixture is subjected to a solvothermal reaction at 120-180°C for 6-8 hours. The reaction product is filtered, dialyzed and freeze-dried to obtain Gd-CDs powder; 2) Gd-CDs were dissolved in PBS, amide activators EDC and NHS were added, and the mixture was allowed to stand at room temperature for 2-4 hours. After activation, PEI was added and stirred at 60-80°C for 4-8 hours. The reaction product was filtered, dialyzed, and freeze-dried to obtain PEI-Gd-CDs powder. 3) Dissolve PEI-Gd-CDs, FA, EDC, and NHS in PBS, stir and react for 12 to 24 hours at room temperature in the dark, and filter, dialyze, and freeze-dry the reaction product to obtain FA-PEI-Gd-CDs solid powder; 4) FA-PEI-Gd-CDs carrying positive charge and VEGF siRNA carrying negative charge were mixed and allowed to stand, and then combined by electrostatic interaction to form a gene-carrying complex FA-PEI-Gd-CDs@VEGF siRNA.
9. The method for preparing the VEGF siRNA-carrying carbon dot complex according to claim 8, characterized in that The solution was filtered using a disposable filter membrane with a pore size of 0.22 μm and dialyzed using a dialysis bag with a molecular weight of 1000 Da.
10. Use of the VEGF siRNA-carrying carbon dot complex according to claim 5 in the preparation of a drug for inhibiting the growth of liver tumor cells.
Citation Information
Patent Citations
Orange-light carbon quantum dots as well as preparation and application thereof
CN113583670A
Red light gadolinium-doped carbon dots and preparation method and application thereof
CN118496853A
Highly-multiplexed fluorescent imaging
US20180030504A1
